Metabolic syndrome in youth with bipolar spectrum disorders treated with second-generation antipsychotics: baseline results from the community-based pragmatic MOBILITY Trial
Abstract
Metabolic syndrome (MetS) in obese youth in the general population is about 29%. The aim of this study is to identify the baseline prevalence and clinical characteristics of MetS in a sample of overweight/obese youth with bipolar spectrum disorders treated with second-generation antipsychotics (SGAs). The MOBILITY trial enrolled overweight/obese youth 8-19 years of age with a lifetime diagnosis of a bipolar spectrum disorder who were continuing or starting treatment with an SGA (November/2015-December/2022). Baseline height, weight, body mass index (BMI), blood pressure, fasting lipid profile, glucose, hemoglobin A1c, and insulin were collected. Logistic regression was used to estimate the odds of MetS and each of its component criteria and correlations with demographic factors. Of 1565 randomized patients mean age = 13.9 ± 2.8 years, males = 53%, White = 65.4%, Black/African American = 18.5%, multiracial = 9.6%, obese = 65.7%, overweight = 34.3%, MetS status could be determined for 996 patients (63.6%). The overall prevalence of MetS was 32.8% (males = 49.5%, females = 26.0%, p < 0.001), being higher in obese than overweight youth (41.1% vs 4.1%, p < 0.001). The odds of MetS increased rapidly with age in boys (p < 0.001); no association with age was evident among girls. White patients having significantly higher frequency of MetS than Black/African American patients (35.5% vs 24.9%, OR = 1.75, p = 0.003). The prevalence of MetS in this enriched sample was about one-third…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 1,565 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.